MwanzoBEAM • NASDAQ
add
Beam Therapeutics Inc
$ 19.52
Kabla ya soko:(0.20%)+0.040
$ 19.56
Imefungwa: 28 Apr, 04:49:36 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 20.17
Bei za siku
$ 19.39 - $ 19.97
Bei za mwaka
$ 13.53 - $ 35.25
Thamani ya kampuni katika soko
1.96B USD
Wastani wa hisa zilizouzwa
2.65M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 30.07M | -90.49% |
Matumizi ya uendeshaji wa biashara | 28.66M | -33.74% |
Mapato halisi | -90.35M | -163.27% |
Kiwango cha faida halisi | -300.51 | -765.43% |
Mapato kwa kila hisa | -1.09 | -163.01% |
EBITDA | -94.59M | -168.44% |
Asilimia ya kodi ya mapato | 0.00% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 850.74M | -28.50% |
Jumla ya mali | 1.10B | -24.38% |
Jumla ya dhima | 370.28M | -22.60% |
Jumla ya hisa | 733.54M | — |
hisa zilizosalia | 81.11M | — |
Uwiano wa bei na thamani | 2.23 | — |
Faida inayotokana na mali | -21.98% | — |
Faida inayotokana mtaji | -27.06% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -90.35M | -163.27% |
Pesa kutokana na shughuli | -76.36M | -156.54% |
Pesa kutokana na uwekezaji | 126.28M | 28.73% |
Pesa kutokana na ufadhili | 3.44M | -89.78% |
Mabadiliko halisi ya pesa taslimu | 53.36M | -80.01% |
Mtiririko huru wa pesa | -22.18M | -123.15% |
Kuhusu
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2017
Tovuti
Wafanyakazi
483
